Bank of America
PLX icon

Bank of America’s Protalix BioTherapeutics PLX Stock Holding History

Bank of America’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$172K Buy
79,079
+32,727
+71% +$81.2K ﹤0.01% 5411
2025
Q4 		$83.4K Buy
46,352
+26,233
+130% +$53.6K ﹤0.01% 5678
2025
Q3 		$44.7K Sell
20,119
-1,773
-8% -$2.89K ﹤0.01% 6868
2025
Q2 		$32.4K Buy
21,892
+21,886
+364,767% +$44.8K ﹤0.01% 6934
2025
Q1 		$16 Sell
6
-33,708
-100% -$80.5K ﹤0.01% 8167
2024
Q4 		$63.4K Sell
33,714
-11,280
-25% -$16K ﹤0.01% 6561
2024
Q3 		$45.9K Sell
44,994
-66,170
-60% -$69.6K ﹤0.01% 6569
2024
Q2 		$130K Sell
111,164
-3,396
-3% -$4.01K ﹤0.01% 6123
2024
Q1 		$144K Sell
114,560
-88,558
-44% -$132K ﹤0.01% 6053
2023
Q4 		$362K Buy
203,118
+29,703
+17% +$46.2K ﹤0.01% 5731
2023
Q3 		$288K Buy
173,415
+102,651
+145% +$184K ﹤0.01% 5684
2023
Q2 		$142K Buy
70,764
+70,725
+181,346% +$168K ﹤0.01% 6046
2023
Q1 		$82 Sell
39
-2,928
-99% -$5.14K ﹤0.01% 7494
2022
Q4 		$4.07K Sell
2,967
-60
-2% -$66 ﹤0.01% 7098
2022
Q3 		$3K Sell
3,027
-477
-14% -$528 ﹤0.01% 7515
2022
Q2 		$4K Sell
3,504
-1,649
-32% -$1.93K ﹤0.01% 7651
2022
Q1 		$5K Sell
5,153
-12,234
-70% -$11.2K ﹤0.01% 7899
2021
Q4 		$14K Buy
17,387
+8,497
+96% +$8.9K ﹤0.01% 7621
2021
Q3 		$12K Buy
8,890
+3,017
+51% +$4.58K ﹤0.01% 7527
2021
Q2 		$11K Sell
5,873
-997
-15% -$3.43K ﹤0.01% 7277
2021
Q1 		$31K Buy
6,870
+6,648
+2,995% +$31K ﹤0.01% 6774
2020
Q4 		$1K Hold
222
– – ﹤0.01% 7011
2020
Q3 		$1K Hold
222
– – ﹤0.01% 6783
2020
Q2 		$1K Buy
222
+191
+616% +$653 ﹤0.01% 6745
2020
Q1 		$0 Buy
+31
New +$103 ﹤0.01% 7152
2019
Q4 		– Sell
-31
Closed – – 7322
2019
Q3 		$0 Hold
31
– – ﹤0.01% 7449
2019
Q2 		$0 Hold
31
– – ﹤0.01% 7359
2019
Q1 		$0 Hold
31
– – ﹤0.01% 7346
2018
Q4 		$0 Sell
31
-1,829
-98% -$8.69K ﹤0.01% 7313
2018
Q3 		$13K Buy
1,860
+1,000
+116% +$5.02K ﹤0.01% 6597
2018
Q2 		$3K Hold
860
– – ﹤0.01% 6874
2018
Q1 		$4K Sell
860
-281
-25% -$1.85K ﹤0.01% 6811
2017
Q4 		$7K Buy
1,141
+310
+37% +$2.09K ﹤0.01% 6682
2017
Q3 		$5K Sell
831
-1,034
-55% -$6.62K ﹤0.01% 6734
2017
Q2 		$16K Buy
1,865
+567
+44% +$5.32K ﹤0.01% 6290
2017
Q1 		$18K Buy
1,298
+1,058
+441% +$9.51K ﹤0.01% 6349
2016
Q4 		$1K Sell
240
-80
-25% -$357 ﹤0.01% 6920
2016
Q3 		$1K Hold
320
– – ﹤0.01% 6954
2016
Q2 		$3K Hold
320
– – ﹤0.01% 6814
2016
Q1 		$3K Hold
320
– – ﹤0.01% 6705
2015
Q4 		$3K Hold
320
– – ﹤0.01% 7023
2015
Q3 		$4K Hold
320
– – ﹤0.01% 6832
2015
Q2 		$7K Hold
320
– – ﹤0.01% 6711
2015
Q1 		$5K Buy
320
+168
+111% +$3.29K ﹤0.01% 6506
2014
Q4 		$2K Sell
152
-1,420
-90% -$30.5K ﹤0.01% 7489
2014
Q3 		$38K Buy
1,572
+1,420
+934% +$40.9K ﹤0.01% 6687
2014
Q2 		$6K Sell
152
-740
-83% -$29.8K ﹤0.01% 7610
2014
Q1 		$41K Buy
892
+160
+22% +$7.47K ﹤0.01% 6542
2013
Q4 		$28K Buy
732
+400
+120% +$16.8K ﹤0.01% 6875
2013
Q3 		$15K Buy
332
+260
+361% +$13.3K ﹤0.01% 7011
2013
Q2 		$4K Buy
+72
New +$3.82K ﹤0.01% 7402

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America's PLX Position: Q1 2026 in Review

Bank of America increased its Protalix BioTherapeutics (PLX) stake by 71% in Q1 2026, buying an estimated $81.2K and bringing the position to 79,079 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #5411.

Bank of America first reported a position in PLX in Q2 2013 and has held it in 51 quarters since. The position peaked at $362K in Q4 2023. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Bank of America held 79,079 shares of Protalix BioTherapeutics worth $172K as of Q1 2026.
  • Bank of America bought 32,727 Protalix BioTherapeutics shares in Q1 2026, an estimated $81.2K.
  • Protalix BioTherapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5411 holding.
  • Bank of America first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 51 quarters since.
  • Bank of America's Protalix BioTherapeutics position peaked at $362K in Q4 2023.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.